Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Treatment With Adebrelimab in Combination With Nimotuzumab and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Single-arm, Exploratory Phase II Clinical Study

NCT07388095 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT07388095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07388095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Treatment With Adebrelimab in Combination With Nimotuzumab and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Single-arm, Exploratory Phase II Clinical Study
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 15, 2026
Completion date
February 28, 2028
Enrollment
22 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

escc